4basebio PLC (4BB.L)

1,045.00 0.00 (0.00%) At close: 04:29PM BST

4basebio PLC

25 Norman Way
Over
Cambridge CB24 5QE
United Kingdom
44 1223 967 943
https://www.4basebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 78

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Heikki Lanckriet Ph.D.	CEO, Chief Scientific Officer & Executive Director	448.9k	N/A	1977
Mr. David Roth	CFO, Company Secretary & Executive Director	323.1k	N/A	1967
Mr. Mark Cooper	Head of Manufacturing	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. It provides AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. The company offers access to its targeted non-viral delivery platform, Hermes. It serves biotech, pharma, and contract development and manufacturing organization. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is based in Cambridge, the United Kingdom.

Corporate governance

4basebio PLC’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.